Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RPh201 is a botanical drug product developed by Regenera Pharma Ltd, consisting of a purified and stabilized 5% (w/w) extract derived from gum mastic, the resin exudate of the *Pistacia lentiscus* tree. Formulated as a topical oil for the treatment of partial thickness burns, the drug is designed to promote wound healing by stimulating granulation and epithelialization. In addition to its wound-healing properties, RPh201 exhibits anti-inflammatory and antibacterial effects. While initially investigated for burns, its primary clinical development has pivoted toward neurodegenerative and neurological conditions, where it is thought to exert neuroprotective and neuroenhancing effects, particularly in diseases such as nonarteritic anterior ischemic optic neuropathy (NAION) and Alzheimer's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RPh201.